Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Clinical assessment, response to infliximab treatment and HMGB1 expression.

From: Systemic TNF blockade does not modulate synovial expression of the pro-inflammatory mediator HMGB1 in rheumatoid arthritis patients – a prospective clinical study

Pat W Sex Age (years) Disease duration (years) CRP Medication DAS28 Clinical response HMGB1 protein HMGB1mRNA
       MTX Pred   DAS28 ACR ES CG  
1 0 F 55 18 107 17.5 5 * 6.71    1.5 1  
  9     38    6.34 No 0 2 1.5  
2 0 F 52 6 14 7.5 7.5 6.00    1.5 1.5  
  9     15    4.43 Mod 20 1 0.5 0
3 0 F 58 2 46 10   7.91    3 4  
  9     25    5.41 Mod 50 1 1.5 0
4 0 F 57 4 7 10   4.94    2 2  
  9     34    4.41 No 20 2 2 Up
5 0 M 56 7 44 15   5.95    2 2.5  
  9     7    2.90 G 70 3.5 3  
6 0 F 69 1 69 15 5 7.39    2 3  
  9     7    1.79 G 70 1.5 2.5 Up
7 0 F 66 14 34 10   5.64    2 2  
  9     16    4.73 Mod 0 1 0.5 Down
8 0 F 66 10 18 12.5   4.83    3.5 4  
  9     19    4.23 Mod 0 0.5 2 Down
9 0 M 25 0.6 26 17.5 7.5 5.62    .5 3  
  9     25    3.91 Mod 20 3 4  
  1. * Patient 1 also received 150 mg/day cyclosporine before and during the study period.Pat = Patient, W = week, CRP = C-reactive protein, MTX = Methotrexate (mg/week), Pred = Prednisone (mg/day), DAS28 = disease activity score calculated on 28 joints, ACR = American College of Rheumatology, HMGB1 = High-mobility group box chromosomal protein 1, ES = Erik Sundberg, CG = Cecilia Grundtman, F = Female, M = Male, No = Non, Mod = Moderate, G = Good.